Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurizon TherapeuticsFRA:ECQ0 +2.08% Equity-to-Asset is 0.54 as of Dec. 2025, which is 33% below its 10-year median of 0.81. The stock has 2 warning signs investors should review. Among 1,414 Biotechnology companies, Neurizon Therapeutics ranks worse than 63.37% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Neurizon Therapeutics Equity-to-Asset Related Terms
Neurizon Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Neurizon Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ECQ0 vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Neurizon Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurizon Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neurizon Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Neurizon Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Neurizon Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurizon Therapeutics (FRA:ECQ0) has a Equity-to-Asset of 0.54 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Neurizon Therapeutics and its competitors. This is 33% below median its historical median of 0.81. Over the past decade, Neurizon Therapeutics' Equity-to-Asset has ranged from 0.54 to 0.92. According to the industry distribution chart, Neurizon Therapeutics ranks #896 out of 1414 companies in the Biotechnology industry, placing it in the top 63.4%.
Is Neurizon Therapeutics' Equity-to-Asset too high?
Neurizon Therapeutics' current Equity-to-Asset of 0.54 is 33% below median its 10-year median of 0.81. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 0.92. The Biotechnology industry median Equity-to-Asset is 0.68. Neurizon Therapeutics' value of 0.54 is 20.6% below this industry median. Based on the distribution chart, Neurizon Therapeutics ranks #896 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint.
How does Neurizon Therapeutics' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurizon Therapeutics ranks #896 out of 1414 companies for Equity-to-Asset. This places Neurizon Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Neurizon Therapeutics' value of 0.54 is 20.6% below this benchmark. Historically, Neurizon Therapeutics' own Equity-to-Asset has ranged from 0.54 to 0.92 over the past decade. While the company's 10-year median is 0.81 vs. the industry median of 0.68, Neurizon Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurizon Therapeutics's current Equity-to-Asset of 0.54 is 20.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Neurizon Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurizon Therapeutics's current Equity-to-Asset is 0.54, which is 33% below median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurizon Therapeutics stock overvalued right now?
Neurizon Therapeutics (FRA:ECQ0) has a current Equity-to-Asset of 0.54. The current Equity-to-Asset is 0.54, which is 33% below median its 10-year median of 0.81 and 20.6% below the Biotechnology industry median of 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Neurizon Therapeutics (FRA:ECQ0), the current Equity-to-Asset is 0.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECQ0 has been successfully added to your 
